Autolus Therapeutics plc
AUTL
$1.59
$0.117.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.13M | 29.93M | 9.01M | 10.12M | 10.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.13M | 29.93M | 9.01M | 10.12M | 10.09M |
| Cost of Revenue | 265.50M | 249.29M | 224.36M | 210.35M | 189.37M |
| Gross Profit | -214.37M | -219.35M | -215.35M | -200.23M | -179.28M |
| SG&A Expenses | 138.56M | 129.61M | 121.25M | 109.89M | 91.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 325.07M | 299.91M | 276.28M | 250.91M | 228.29M |
| Operating Income | -273.94M | -269.97M | -267.27M | -240.79M | -218.20M |
| Income Before Tax | -220.19M | -223.67M | -234.37M | -219.14M | -270.19M |
| Income Tax Expenses | 4.62M | 4.11M | 3.76M | 1.53M | 41.00K |
| Earnings from Continuing Operations | -224.80 | -227.78 | -238.13 | -220.66 | -270.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -224.80M | -227.78M | -238.13M | -220.66M | -270.23M |
| EBIT | -273.94M | -269.97M | -267.27M | -240.79M | -218.20M |
| EBITDA | -264.68M | -261.31M | -259.08M | -233.07M | -210.78M |
| EPS Basic | -0.84 | -0.86 | -0.89 | -0.87 | -1.21 |
| Normalized Basic EPS | -0.52 | -0.52 | -0.55 | -0.54 | -0.75 |
| EPS Diluted | -0.84 | -0.86 | -0.89 | -0.87 | -1.21 |
| Normalized Diluted EPS | -0.52 | -0.52 | -0.55 | -0.54 | -0.75 |
| Average Basic Shares Outstanding | 1.06B | 1.06B | 1.06B | 1.02B | 928.38M |
| Average Diluted Shares Outstanding | 1.06B | 1.06B | 1.06B | 1.02B | 928.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |